John G. Webb

Worldwide Transcatheter Treatment Procedures and Heart Valve Industry to 2025 - Major Developments Influencing the Market - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 11, 2021

The "Transcatheter Treatment: Procedures and Heart Valve Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Transcatheter Treatment: Procedures and Heart Valve Market" report has been added to ResearchAndMarkets.com's offering.
  • Transcatheter treatment includes procedure types such as TAVR, TAVI, TMVR and TMVI.
  • Transcatheter procedure approaches include transfemoral, transapical and transaortic procedures.
  • This report is an analytical business tool with the primary purpose of providing a thorough evaluation of the global market for transcatheter treatment for heart valve diseases.

Valcare Medical Announces First-in-Human Transseptal Implant of the AMEND™ Annuloplasty Ring for Mitral Valve Repair

Retrieved on: 
Wednesday, January 27, 2021

HERZLIYA, Israel, Jan. 27, 2021 /PRNewswire/ -- Valcare Medical Ltd. developer of transcatheter mitral and tricuspid valve repair and replacement solutions, announces that it has successfully completed its first-in-human transseptal delivery of the AMENDannuloplasty ring.

Key Points: 
  • HERZLIYA, Israel, Jan. 27, 2021 /PRNewswire/ -- Valcare Medical Ltd. developer of transcatheter mitral and tricuspid valve repair and replacement solutions, announces that it has successfully completed its first-in-human transseptal delivery of the AMENDannuloplasty ring.
  • Valcare's AMEND mitral valve repair device is an innovative, clinically proven, D-shaped, semi-rigid closed ring with unique anchoring capabilities.
  • Following demonstration of safety and efficacy of the AMEND ring in transapical procedures, we are now delivering this D-shaped annuloplasty ring via a transseptal approach.
  • Valcare Medical is a privately held medical device company, dedicated to providing innovative transcatheter technologies for the treatment of mitral and tricuspid regurgitation.

Valcare Medical Announces First-in-Human Transseptal Implant of the AMEND™ Annuloplasty Ring for Mitral Valve Repair

Retrieved on: 
Wednesday, January 27, 2021

HERZLIYA, Israel, Jan. 27, 2021 /PRNewswire/ -- Valcare Medical Ltd. developer of transcatheter mitral and tricuspid valve repair and replacement solutions, announces that it has successfully completed its first-in-human transseptal delivery of the AMENDannuloplasty ring.

Key Points: 
  • HERZLIYA, Israel, Jan. 27, 2021 /PRNewswire/ -- Valcare Medical Ltd. developer of transcatheter mitral and tricuspid valve repair and replacement solutions, announces that it has successfully completed its first-in-human transseptal delivery of the AMENDannuloplasty ring.
  • Valcare's AMEND mitral valve repair device is an innovative, clinically proven, D-shaped, semi-rigid closed ring with unique anchoring capabilities.
  • Following demonstration of safety and efficacy of the AMEND ring in transapical procedures, we are now delivering this D-shaped annuloplasty ring via a transseptal approach.
  • Valcare Medical is a privately held medical device company, dedicated to providing innovative transcatheter technologies for the treatment of mitral and tricuspid regurgitation.

Transcatheter Mitral Valve Implantation Market Size Worth USD 4.67 Billion By 2027 | CAGR of 14.4%: Emergen Research

Retrieved on: 
Wednesday, September 23, 2020

Transcatheter Mitral Valve Implantation Market Size USD 1.82 billion in 2019, Transcatheter Mitral Valve Implantation Market Growth CAGR of 14.4%, Transcatheter Mitral Valve Implantation Industry Trends percutaneous transcatheter mitral valve replacement techniques, favorable investment opportunities, and technological advancements

Key Points: 
  • Transcatheter Mitral Valve Implantation Market Size USD 1.82 billion in 2019, Transcatheter Mitral Valve Implantation Market Growth CAGR of 14.4%, Transcatheter Mitral Valve Implantation Industry Trends percutaneous transcatheter mitral valve replacement techniques, favorable investment opportunities, and technological advancements
    According to the current analysis of Emergen Research, the Global Transcatheter Mitral Valve Implantation Market was valued at USD 1.82 billion in 2019 and is expected to reach USD 4.67 billion by 2027, at a CAGR of 14.4%.
  • Rising incidences of mitral valve diseases, new pipeline devices, together with the increasing elderly population with heart conditions, is positively driving the growth of the Transcatheter Mitral Valve Implantation (repair and replacement) market in the forecast period.
  • A practicable and comparatively safe option in patients with mitral regurgitation is called percutaneous transcatheter mitral valve replacement.
  • The escalating demand for this technique is enhancing the growth prospects of the global transcatheter mitral valve implantation market over the forecast period.

Transcatheter Mitral Valve Implantation Market Size Worth USD 4.67 Billion By 2027 | CAGR of 14.4%: Emergen Research

Retrieved on: 
Wednesday, September 23, 2020

- Advancements in the techniques of Transcatheter Mitral Valve Implantation and substantial prevalence of Mitral Regurgitation with favorable reimbursement scenarios are expected to fuel the market growth.

Key Points: 
  • - Advancements in the techniques of Transcatheter Mitral Valve Implantation and substantial prevalence of Mitral Regurgitation with favorable reimbursement scenarios are expected to fuel the market growth.
  • Transcatheter Mitral Valve Implantation Market Size USD 1.82 billion in 2019, Transcatheter Mitral Valve Implantation Market Growth CAGR of 14.4%, Transcatheter Mitral Valve Implantation Industry Trends percutaneous transcatheter mitral valve replacement techniques, favorable investment opportunities, and technological advancements
    According to the current analysis of Emergen Research, the Global Transcatheter Mitral Valve Implantation Market was valued at USD 1.82 billion in 2019 and is expected to reach USD 4.67 billion by 2027, at a CAGR of 14.4%.
  • Rising incidences of mitral valve diseases, new pipeline devices, together with the increasing elderly population with heart conditions, is positively driving the growth of the Transcatheter Mitral Valve Implantation (repair and replacement) market in the forecast period.
  • The escalating demand for this technique is enhancing the growth prospects of the global transcatheter mitral valve implantation market over the forecast period.

Northwestern Medicine Celebrates 2000th Transcatheter Heart Valve Procedure

Retrieved on: 
Wednesday, August 26, 2020

CHICAGO, Aug. 26, 2020 /PRNewswire/ -- Northwestern Medicine Bluhm Cardiovascular Institute physicians recently completed their 2000th transcatheter heart valve procedure, a milestone innovation that has shifted valve repair and replacement from operating room to catherization lab, dramatically reducing procedural time, recovery time and mortality risk for thousands of patients with heart valve disease.

Key Points: 
  • CHICAGO, Aug. 26, 2020 /PRNewswire/ -- Northwestern Medicine Bluhm Cardiovascular Institute physicians recently completed their 2000th transcatheter heart valve procedure, a milestone innovation that has shifted valve repair and replacement from operating room to catherization lab, dramatically reducing procedural time, recovery time and mortality risk for thousands of patients with heart valve disease.
  • Physicians at Northwestern Medicine Central DuPage Hospital, who recently completed their 200th transcatheter valve replacement, also contributed to the 2,000th milestone.
  • Northwestern Memorial Hospital performs the highest volume of transcatheter and surgical valve procedures in Illinois, having completed the most aortic, mitral and tricuspid valve procedures in the state.
  • Currently, there are 18 transcatheter valve trials, including 5 early feasibility studies, the critical first clinical step of research and development, and the first-in-human transcatheter trials for the tricuspid valve.

Transcatheter Aortic Valve Replacement (TAVR) Market 2020-2024: Transfemoral, Transapical and Transaortic

Retrieved on: 
Thursday, April 23, 2020

DUBLIN, April 23, 2020 /PRNewswire/ -- The "Global Transcatheter Aortic Valve Replacement (TAVR) Market (Transfemoral, Transapical & Transaortic): Insights, Trends & Forecast (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 23, 2020 /PRNewswire/ -- The "Global Transcatheter Aortic Valve Replacement (TAVR) Market (Transfemoral, Transapical & Transaortic): Insights, Trends & Forecast (2020-2024)" report has been added to ResearchAndMarkets.com's offering.
  • The global transcatheter aortic valve replacement (TAVR) market by procedure can be segmented into the following three categories: transfemoral, transapical and transaortic.
  • The global transcatheter aortic valve replacement (TAVR) market by region can be segmented as follows: the US and outside the US.
  • The report provides a comprehensive analysis of the global transcatheter aortic valve replacement (TAVR) market, segmented into transfemoral, transapical and transaortic procedures.

Global Transcatheter Aortic Valve Replacement Market: Insights, Trends & Forecast (2020-2024) - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 9, 2020

The "Global Transcatheter Aortic Valve Replacement (TAVR) Market (Transfemoral, Transapical & Transaortic): Insights, Trends & Forecast (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Transcatheter Aortic Valve Replacement (TAVR) Market (Transfemoral, Transapical & Transaortic): Insights, Trends & Forecast (2020-2024)" report has been added to ResearchAndMarkets.com's offering.
  • The market growth of transcatheter aortic valve replacement (TAVR) was supported by various factors like rising prevalence of aortic stenosis, increasing GDP per capita, growing obese population and increasing healthcare spending.
  • The global transcatheter aortic valve replacement (TAVR) market by procedure can be segmented into the following three categories: transfemoral, transapical and transaortic.
  • The global transcatheter aortic valve replacement (TAVR) market by region can be segmented as follows: the US and outside the US.

TriGUARD 3™ Cerebral Embolic Protection Device Receives CE Mark for Use in Transcatheter Heart Procedures

Retrieved on: 
Tuesday, March 10, 2020

TAMPA, Fla., March 10, 2020 /PRNewswire/ -- Keystone Heart Ltd., a Venus Medtech Company, today announced European CE Mark for the TriGUARD 3 Cerebral Embolic Protection (CEP) Device.

Key Points: 
  • TAMPA, Fla., March 10, 2020 /PRNewswire/ -- Keystone Heart Ltd., a Venus Medtech Company, today announced European CE Mark for the TriGUARD 3 Cerebral Embolic Protection (CEP) Device.
  • The device is designed to minimize the risk of cerebral damage by deflecting embolic debris away from cerebral circulation during Transcatheter Aortic Valve Implantation (TAVI) and other transcatheter heart procedures.
  • The TriGUARD 3 CEP device is the only CE Marked product designed to cover and protect all three major cerebral aortic arch vessels.
  • Keystone Heart recently completed the REFLECT Trial (a pivotal randomized trial of the TriGUARD 3 CEP device).

TriGUARD 3™ Cerebral Embolic Protection Device Receives CE Mark for Use in Transcatheter Heart Procedures

Retrieved on: 
Tuesday, March 10, 2020

TAMPA, Florida, March 10, 2020 /PRNewswire/ -- Keystone Heart Ltd., a Venus Medtech Company, today announced European CE Mark for the TriGUARD 3 Cerebral Embolic Protection (CEP) Device.

Key Points: 
  • TAMPA, Florida, March 10, 2020 /PRNewswire/ -- Keystone Heart Ltd., a Venus Medtech Company, today announced European CE Mark for the TriGUARD 3 Cerebral Embolic Protection (CEP) Device.
  • The device is designed to minimize the risk of cerebral damage by deflecting embolic debris away from cerebral circulation during Transcatheter Aortic Valve Implantation (TAVI) and other transcatheter heart procedures.
  • The TriGUARD 3 CEP device is the only CE Marked product designed to cover and protect all three major cerebral aortic arch vessels.
  • Keystone Heart recently completed the REFLECT Trial (a pivotal randomized trial of the TriGUARD 3 CEP device).